Abstract CT017: Pan-mutant and Isoform Selective PI3Kα Inhibitor, RLY-2608, Demonstrates Selective Targeting in a First-in-human Study of PIK3CA-mutant Solid Tumor Patients, ReDiscover Trial
Cancer research(2023)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined